Chattanooga, Tenn.-based Advanced Catheter Therapies received FDA 510(k) clearance for its Occlusion Perfusion Catheter, a multi-lumen balloon catheter on Tuesday. The medical device technology can measure pressure inside the treatment chamber, as well as “its inflow and outflow ports for chamber evacuation, filling and flushing,” according to a press release. The catheter is designed to deliver therapeutic agents locally to the peripheral and “eventually” coronary vasculature.
“It marks a significant advance for ACT and our lead product, and we look forward to finding a partner to move the OPC forward to full commercialization,” ACT CEO Paul Fitzpatrick said in the release. ACT is in the middle of raising a $3 million Series B round of preferred equity financing, and focuses on catheter technologies for vascular disease.
